FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

	.,		

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden

hours per response

0.5

1	Check this box if no longer subject to							
	Section 16. Form 4 or Form 5 obligations may continue. See							
J	obligations may continue. See							
	Instruction 1(b).							

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*					2. Issuer Name and Ticker or Trading Symbol SANGAMO THERAPEUTICS, INC [ SGMO							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
Macrae Sandy				j	]							Director Officer (give title below)		10% Ov Other (s below)	· I	
(Last) (First) (Middle) C/O SANGAMO THERAPEUTICS, INC. POINT RICHMOND TECH CNTR, 501 CANAL BLVD				0	3. Date of Earliest Transaction (Month/Day/Year) 01/26/2017							President and CEO				
(Street) RICHMOND CA 94804			94804	4.	4. If Amendment, Date of Original Filed (Month/Day/Year)					Lin	Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)													
		Та	ble I - Non-D	erivati	ve Se	ecurities	s Ac	quired, D	isposed	of, or Be	neficial	y Owned				
1. Title of Security (Instr. 3)  2. Trans: Date (Month/L						2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.		red (A) or str. 3, 4 and	Beneficia Owned F	s Forn ally (D) o following (I) (Ir	orm: Direct )) or Indirect ) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
							Code V	Amount	(A) (D)	Price	Reported Transacti (Instr. 3 a	ion(s)		(Instr. 4)		
			Table II - Der (e.g					uired, Dis s, options				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code (	ansaction Derivation Securification Acquired or Discontinuing of (D)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)				ties ng e Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(5)		
Employee Stock Option (Right to Buy)	\$3.5	01/26/2017		A		360,000		(1)	01/25/2027	Common Stock	360,000	\$0	360,000	D		

## **Explanation of Responses:**

1. The stock option vests and becomes exercisable for 25% of the shares upon the Reporting Person's completion of one year of service measured from the grant date, and the balance of the shares will vest and become exercisable in 36 successive equal monthly installments upon his completion of each additional month of service thereafter.

/s/ Florence Tam, Attorney-in-

**Fact** 

\*\* Signature of Reporting Person

Date

01/30/2017

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.